Show simple item record

dc.contributor.authorMiranda Cadena, Katherine
dc.contributor.authorMarcos Arias, Cristina
dc.contributor.authorPérez Rodríguez, Aitzol ORCID
dc.contributor.authorCabello Beitia, Iván
dc.contributor.authorMateo Alesanco, Estibaliz ORCID
dc.contributor.authorSevillano Peña, Elena
dc.contributor.authorMadariaga Torres, Lucila ORCID
dc.contributor.authorQuindós Andrés, Guillermo
dc.contributor.authorEraso Barrio, María Elena ORCID
dc.date.accessioned2022-05-26T07:49:30Z
dc.date.available2022-05-26T07:49:30Z
dc.date.issued2022
dc.identifier.citationJournal of Oral Microbiology 14(1) : (2022) // Article ID 2045813es_ES
dc.identifier.issn2000-2297
dc.identifier.urihttp://hdl.handle.net/10810/56734
dc.description.abstract[EN] Background The ability of Candida to develop biofilms on inert surfaces or living tissues favors recalcitrant and chronic candidiasis associated, in many instances, with resistance to current antifungal therapy. Aim The aim of this study was to evaluate the antifungal activity of citral, a phytocompound present in lemongrass essential oil, in monotherapy and combined with fluconazole against azole-resistant Candida planktonic cells and biofilms. The effect of citral combined with fluconazole was also analysed with regard to the expression of fluconazole resistance-associated genes in Candida albicans and the effectiveness of the combination therapy in a Caenorhabditis elegans model of candidiasis. Results Citral reduced biofilm formation at initial stages and the metabolic activity of the mature biofilm. The combination of citral with fluconazole was synergistic, with a significant increase in the survival of C. elegans infected with Candida. RNA analysis revealed a reduction of the expression of the efflux pump encoded by MDR1, leading to a greater effect of fluconazole. Conclusion Citral in monotherapy and in combination with fluconazole could represent an interesting therapy to treat recalcitrant Candida infections associated to biofilms.es_ES
dc.description.sponsorshipThis research was supported by Gobierno Vasco-Eusko Jaurlaritza [Eusko Jaurlaritza GIC15/78 IT-990-16] and by Fundacion ONCE "Oportunidad al Talento" and Fondo Social Europeo CM-A [C.M.-A.]; Ministerio de Economia, Industria y Competitividad, Gobierno de Espan [PID2020-117983RB-I00].es_ES
dc.language.isoenges_ES
dc.publisherTaylor & Francises_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/PID2020-117983RB-I00es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.subjectcandidaes_ES
dc.subjectbiofilmes_ES
dc.subjectcitrales_ES
dc.subjectazole resistancees_ES
dc.subjectcaenorhabditis eleganses_ES
dc.subjectgene expressiones_ES
dc.titleIn vitro and in vivo anti-Candida activity of citral in combination with fluconazolees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.es_ES
dc.rights.holderAtribución-NoComercial 3.0 España*
dc.relation.publisherversionhttps://www.tandfonline.com/doi/full/10.1080/20002297.2022.2045813es_ES
dc.identifier.doi10.1080/20002297.2022.2045813
dc.departamentoesInmunología, microbiología y parasitologíaes_ES
dc.departamentoeuImmunologia, mikrobiologia eta parasitologiaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.